The discovery of pathogenic variants (PVs) in the Breast Cancer Gene 1 (BRCA1) and Breast Cancer Gene 2 (BRCA2) genes, which account for approximately 10–15% of non-mucinous epithelial ovarian cancers (EOC), has revolutionised the management of this disease [1,2,3]. This evidence concerns the gene BRCA2 and cancer.